BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 38376927)

  • 1. Potentiating the radiation-induced type I interferon antitumoral immune response by ATM inhibition in pancreatic cancer.
    Zhang Q; Jiang L; Wang W; Huber AK; Valvo VM; Jungles KM; Holcomb EA; Pearson AN; The S; Wang Z; Parsels LA; Parsels JD; Wahl DR; Rao A; Sahai V; Lawrence TS; Green MD; Morgan MA
    JCI Insight; 2024 Feb; 9(6):. PubMed ID: 38376927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of ATM Increases Interferon Signaling and Sensitizes Pancreatic Cancer to Immune Checkpoint Blockade Therapy.
    Zhang Q; Green MD; Lang X; Lazarus J; Parsels JD; Wei S; Parsels LA; Shi J; Ramnath N; Wahl DR; Pasca di Magliano M; Frankel TL; Kryczek I; Lei YL; Lawrence TS; Zou W; Morgan MA
    Cancer Res; 2019 Aug; 79(15):3940-3951. PubMed ID: 31101760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ATM inhibition augments type I interferon response and antitumor T-cell immunity when combined with radiation therapy in murine tumor models.
    Jin WJ; Zangl LM; Hyun M; Massoud E; Schroeder K; Alexandridis RA; Morris ZS
    J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37730275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA-PK Inhibition and Radiation Promote Antitumoral Immunity through RNA Polymerase III in Pancreatic Cancer.
    Wang W; McMillan MT; Zhao X; Wang Z; Jiang L; Karnak D; Lima F; Parsels JD; Parsels LA; Lawrence TS; Frankel TL; Morgan MA; Green MD; Zhang Q
    Mol Cancer Res; 2022 Jul; 20(7):1137-1150. PubMed ID: 35348737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Galectin-9 blockade synergizes with ATM inhibition to induce potent anti-tumor immunity.
    Zheng S; Song J; Linghu D; Yang R; Liu B; Xue Z; Chen Q; Liu C; Zhong D; Hung MC; Sun L
    Int J Biol Sci; 2023; 19(3):981-993. PubMed ID: 36778120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ataxia telangiectasia mutated kinase inhibition promotes irradiation-induced PD-L1 expression in tumour-associated macrophages through IFN-I/JAK signalling pathway.
    Gao Y; Li Y; Lin Z; Zeng Y; Huang Z; Han L; Zhong Y; Gong Y; Wu Q; Xie C
    Immunology; 2023 Feb; 168(2):346-361. PubMed ID: 36326481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CRISPR Screen of Druggable Targets in Small Cell Lung Cancer Identified ATM Inhibitor (AZD1390) as a Radiosensitizer.
    Ran X; Wu BX; Shi M; Song L; Nixon K; Philip V; He HH; Tsao MS; Lok BH
    Int J Radiat Oncol Biol Phys; 2024 Apr; 118(5):1308-1314. PubMed ID: 38104868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aberrant ATM signaling and homology-directed DNA repair as a vulnerability of p53-mutant GBM to AZD1390-mediated radiosensitization.
    Chen J; Laverty DJ; Talele S; Bale A; Carlson BL; Porath KA; Bakken KK; Burgenske DM; Decker PA; Vaubel RA; Eckel-Passow JE; Bhargava R; Lou Z; Hamerlik P; Harley B; Elmquist WF; Nagel ZD; Gupta SK; Sarkaria JN
    Sci Transl Med; 2024 Feb; 16(734):eadj5962. PubMed ID: 38354228
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simultaneous Delivery of Dual Inhibitors of DNA Damage Repair Sensitizes Pancreatic Cancer Response to Irreversible Electroporation.
    Long X; Dai A; Huang T; Niu W; Liu L; Xu H; Yin T; Jiang T; Sun S; Lei P; Li C; Zhu X; Zhao J
    ACS Nano; 2023 Jul; 17(13):12915-12932. PubMed ID: 37352467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic Co-targeting of WEE1 and ATM Downregulates PD-L1 Expression in Pancreatic Cancer.
    Jin MH; Nam AR; Park JE; Bang JH; Bang YJ; Oh DY
    Cancer Res Treat; 2020 Jan; 52(1):149-166. PubMed ID: 31291716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Manipulation of Redox Metabolism Using Pharmacologic Ascorbate Opens a Therapeutic Window for Radio-Sensitization by ATM Inhibitors in Colorectal Cancer.
    Callaghan CM; Abukhiran IM; Masaadeh A; Van Rheeden RV; Kalen AL; Rodman SN; Petronek MS; Mapuskar KA; George BN; Coleman MC; Goswami PC; Allen BG; Spitz DR; Caster JM
    Int J Radiat Oncol Biol Phys; 2023 Mar; 115(4):933-944. PubMed ID: 36228747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combining radiation and the ATR inhibitor berzosertib activates STING signaling and enhances immunotherapy via inhibiting SHP1 function in colorectal cancer.
    Liu C; Wang X; Qin W; Tu J; Li C; Zhao W; Ma L; Liu B; Qiu H; Yuan X
    Cancer Commun (Lond); 2023 Apr; 43(4):435-454. PubMed ID: 36855844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intratumoral immunotherapy using a TLR2/3 agonist, L-pampo, induces robust antitumor immune responses and enhances immune checkpoint blockade.
    Lee WS; Kim DS; Kim JH; Heo Y; Yang H; Go EJ; Kim JH; Lee SJ; Ahn BC; Yum JS; Chon HJ; Kim C
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. WEE1 inhibitor and ataxia telangiectasia and RAD3-related inhibitor trigger stimulator of interferon gene-dependent immune response and enhance tumor treatment efficacy through programmed death-ligand 1 blockade.
    Wu X; Kang X; Zhang X; Xie W; Su Y; Liu X; Guo L; Guo E; Li F; Hu D; Qin X; Fu Y; Peng W; Jia J; Wang C
    Cancer Sci; 2021 Nov; 112(11):4444-4456. PubMed ID: 34382294
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RIG-I-like helicases induce immunogenic cell death of pancreatic cancer cells and sensitize tumors toward killing by CD8(+) T cells.
    Duewell P; Steger A; Lohr H; Bourhis H; Hoelz H; Kirchleitner SV; Stieg MR; Grassmann S; Kobold S; Siveke JT; Endres S; Schnurr M
    Cell Death Differ; 2014 Dec; 21(12):1825-37. PubMed ID: 25012502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma.
    Sheng H; Huang Y; Xiao Y; Zhu Z; Shen M; Zhou P; Guo Z; Wang J; Wang H; Dai W; Zhang W; Sun J; Cao C
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sensitizing immune unresponsive colorectal cancers to immune checkpoint inhibitors through MAVS overexpression.
    Hwang BJ; Tsao LC; Acharya CR; Trotter T; Agarwal P; Wei J; Wang T; Yang XY; Lei G; Osada T; Lyerly HK; Morse MA; Hartman ZC
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35361727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective ATM inhibition augments radiation-induced inflammatory signaling and cancer cell death.
    Chiu LY; Sun Q; Zenke FT; Blaukat A; Vassilev LT
    Aging (Albany NY); 2023 Jan; 15(2):492-512. PubMed ID: 36656721
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacology of the ATM Inhibitor AZD0156: Potentiation of Irradiation and Olaparib Responses Preclinically.
    Riches LC; Trinidad AG; Hughes G; Jones GN; Hughes AM; Thomason AG; Gavine P; Cui A; Ling S; Stott J; Clark R; Peel S; Gill P; Goodwin LM; Smith A; Pike KG; Barlaam B; Pass M; O'Connor MJ; Smith G; Cadogan EB
    Mol Cancer Ther; 2020 Jan; 19(1):13-25. PubMed ID: 31534013
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models.
    Oba T; Makino K; Kajihara R; Yokoi T; Araki R; Abe M; Minderman H; Chang AE; Odunsi K; Ito F
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34049930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.